TIDMFIPP
Frontier IP Group plc
13 December 2023
Reach - a non-regulatory announcement
AIM: FIPP
13 December 2023
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - The Vaccine Group announces significant
milestone in the appointment of Advisory Board
Frontier IP, a specialist in commercialising intellectual
property, notes the following announcement that portfolio company
The Vaccine Group ("TVG" or the "Company") has appointed an
Advisory Board to support scale-up of the Company's novel
herpesvirus-based vaccine platform.
The advisory board consists of three high-ranking veterinary
experts with strong business experience and connections to major
companies and other organisations in the animal health sector. The
move reflects the progress TVG has made in establishing a strong
vaccine pipeline.
Neil Crabb, Frontier IP Chief Executive Officer, said : "I am
delighted TVG has been able to form an advisory group of such good
quality. It is a testament to the potential of the Company, its
vaccine platform and pipeline, and I look forward to further
developments as TVG's vaccines move towards scale up and full
commercialisation. "
The Vaccine Group statement begins:
The Vaccine Group announces appointment of Advisory Board
The Vaccine Group ("TVG") has appointed three high-ranking and
well-connected animal health experts to form an advisory board to
support scale up of the Company's novel herpesvirus-based vaccine
platform and to forge deeper industry relationships.
TVG has made strong progress in establishing a pipeline of
vaccines for use in livestock, pets and wildlife to tackle a range
of viral and bacterial pathogens which cause severe economic harm
or, if they are zoonotic, can also pose a threat to human
health.
The advisory board members have extensive veterinary health and
business experience. They are:
Christophe Barnier-Quer: Christophe works for Merck Life Science
in its Contract Development and Manufacturing Organisations branch.
He has a PhD in pharmaceutical science from Leiden University, an
MBA from HEC Paris and 15 years' experience in vaccine R&D,
including as R&D director for GALVmed.
Johan Dreesen: A doctor in veterinary medicine, Johann runs an
animal health consultancy with a focus on start-ups, animal health
pharmaceuticals and non-government organisations. He is a member of
the Advisory Council to Kela Pharma and sits on the GALVmed board.
He received his doctorate from Ghent University and worked in
veterinary practice before leading businesses within Pfizer Animal
Health and Zoetis.
Vaughn Kubiak: Vaughn has more than 40 years' experience in
global animal health in a wide range of senior technical and
managerial roles in major companies across R&D, quality
assurance and quality control, regulatory affairs, product
management and commercial operations. Before retirement in 2019, he
spent 17 years at Zoetis. Vaughn now works as a consultant and sits
on several technical advisory boards. He has a Master of Science
degree in microbiology from Emory University and is involved in the
Scientific Committee of the International Alliance for Biological
Standardisation.
TVG has 12 vaccines currently under development targeting
economically harmful and zoonotic diseases. They include vaccines
for protection against porcine reproductive and respiratory
syndrome, African swine fever, porcine circovirus-2, streptococcus
suis, bovine respiratory syncytial virus and lumpy skin disease.
TVG has also developed a transmissible candidate vaccine for Lassa
fever for use in the rodent reservoir. All vaccines are based on
the Company's tunable herpesvirus based platforms.
Jeremy Salt, Chief Executive of The Vaccine Group, said: "As we
approach the end of another successful year for TVG, it is
especially positive that we can look forward to gaining the support
of three Board Advisors from January. Each of them brings great
expertise in their own areas. This will be really helpful for TVG
as we grow into a strong player in the global animal health
innovation sector."
The Vaccine Group statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 7332 2338
Neil Crabb, Chief Executive Officer neil@frontierip.co.uk
Andrew Johnson, Communications and investor M: 07464 546 025
relations
andrew.johnson@frontierip.co.uk
Company website: www.frontierip.co.uk
The Vaccine Group
Jeremy Salt, Chief Executive Officer jeremy.salt@thevaccinegroup.com
Allenby Capital Limited (Nominated Adviser) T: 0203 328 5656
Nick Athanas / George Payne
ABOUT THE VACCINE GROUP
The Vaccine Group (TVG) was founded in 2017 to develop and
commercialise the recombinant vaccine technology work of Dr Michael
Jarvis, Associate Professor in Virology and Immunology at the
University of Plymouth's School of Biomedical Sciences.
Through a mixed funding model of public grants and private
equity, TVG has established a pipeline of projects that address
infectious diseases in animals that are either zoonotic,
transferred from animals to humans, or have a serious commercial
impact on livestock production, such as PRRS and African Swine
Fever in pigs, and bovine tuberculosis in cattle.
Most emerging infections, especially those with high pandemic
potential in humans, emerge from domestic and wildlife animal
populations.
Due to the earlier ability to test animal vaccines in their
intended host, and the relative speed at which animal compared to
human vaccines are approved for use, vaccination of animals rather
than humans is becoming accepted as an approach to protect humans
against some emerging zoonotic pathogens.
Its business model is to develop vaccine candidates to
proof-of-concept with commercial exploitation delivered through
license agreements with vaccine manufacturing companies.
For more information: www.thevaccinegroup.com
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKBBKBBDBKBD
(END) Dow Jones Newswires
December 13, 2023 02:00 ET (07:00 GMT)
Frontier IP (AQSE:FIPP.GB)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Frontier IP (AQSE:FIPP.GB)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
